Sign In
Buy HRTX
$0.447
-0.0032 (-0.711%)
At Close: Jun 03, 2026
U.S. District Court Issues Decision Regarding CINVANTI® Patents
08:12am, Tuesday, 02'nd Jun 2026
CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. Distri
Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
01:20pm, Monday, 11'th May 2026
Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
Heron Therapeutics Q1 Earnings Call Highlights
11:08am, Monday, 11'th May 2026
Heron Therapeutics NASDAQ: HRTX said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving m
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
10:31am, Monday, 11'th May 2026
The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Stre
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates
10:11am, Monday, 11'th May 2026
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
08:00am, Monday, 11'th May 2026
CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
11:00am, Monday, 04'th May 2026
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
05:30pm, Monday, 27'th Apr 2026
CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company wi
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:55am, Tuesday, 07'th Apr 2026
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript
03:08pm, Thursday, 26'th Feb 2026
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say
01:30pm, Thursday, 26'th Feb 2026
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key met
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
08:00am, Thursday, 26'th Feb 2026
– ZYNRELEF ® and APONVIE ® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise – Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173
Heron: Near The Bottom Of A Trading Range Despite Positives
10:28am, Wednesday, 18'th Feb 2026
HRTX has reported preliminary Q4'25 net revenues, with Zynrelef experiencing a breakout quarter. Aponvie sales are also still growing, with the acute care franchise being able to offset declines in th
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
08:30am, Tuesday, 17'th Feb 2026
CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company wil
New York State Common Retirement Fund Buys 816,671 Shares of Heron Therapeutics, Inc. $HRTX
04:04am, Sunday, 08'th Feb 2026
New York State Common Retirement Fund raised its stake in Heron Therapeutics, Inc. (NASDAQ: HRTX) by 46.4% in the undefined quarter, according to the company in its most recent disclosure with the Sec
